Three US life-sciences companies hitting the market delivered mostly robust early trading after investors strongly supported ...

Shares of Upstream Bio surged on the clinical-stage biotechnology company's first day of trading. Shares jumped 34% to $22.74 in Friday afternoon trading. The company on Thursday said it would offer ...

Upstream Bio (NASDAQ:UPB) shares rallied 32% Friday following the asthma drug developer’s $255M upsized initial public ...

CeriBell (CBLL) shares rallied 35% Friday following the medical device maker’s $180M initial public offering. Read more here.

Shares of Upstream Bio opened 26.5% above the initial public offering price in their Nasdaq debut on Friday, valuing the drug developer at $1.05 billion.

Big amounts of selling in the healthcare-biotech sectors (XBI) could be signaling capitulation, followed by a rally, ...

Two biotechs set out for the public markets this week, with Upstream Bio raising $255 million for its inflammatory disease ...

The average IG bond spread edged in by 1bp to 84bp, a record post financial crisis low, on Thursday, and the HY bond spread gapped out by 5bp to 299bp, according to ICE BofA data.

This summary provides a snapshot of current health news, including IPO pricing by biotech startups, Sanofi's potential sale of its consumer health business, HMI Medical's acquisition in Singapore, a ...

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

Three U.S. healthcare startups priced their initial public offerings (IPO) on Thursday, including Upstream Bio which raised ...